Roka Bioscience announced that its Atlas STEC EG2 Combo Detection Assay has received AOAC Performance Tested MethodsSM certification from the AOAC Research Institute (AOAC-RI). The independent laboratory study was conducted by Silliker Inc., as part of the AOAC-RI independent third- party validation process.
The Atlas STEC EG2 Combo Detection Assay is approved for the detection of E. coli O157:H7 and other non-O157:H7 Shiga toxin-producing E. coli (STEC). The assay requires only one transfer step and a single transfer tube for the detection of both E. coli O157:H7 and non-O157 STEC. The addition of the Atlas STEC EG2 Combo Assay provides a second E. coli screening option to Roka’s E. coli O157:H7 specific test as well as its assays for the detection of Listeria spp., Salmonella, and Listeria monocytogenes.
Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our “sample-in, result-out” Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies. For more information, visit www.rokabio.com.
The AOAC Research Institute (AOAC-RI) is a wholly owned subsidiary of AOAC INTERNATIONAL (AOAC) that administers AOAC's conformity assessment, including the AOACPerformance Tested Methods program. AOAC is a globally recognized, independent, not-for-profit standards developing association founded in 1884. AOAC serves the analytical community by engaging industry stakeholders to develop voluntary consensus standards for methods and providing analytical methods that demonstrate confidence in analytical results. For more information on the AOAC-RI and AOAC, visit the AOAC website at www.aoac.org.